Randall T. Higashida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Randall T. Higashida has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Christopher F. Dowd
8 shared publications- Van V. Halbach
Division of Interventional Neuroradiology, University of California at San Francisco Medical Center, San Francisco, California
7 shared publications Perry P. Ng
Division of Interventional Neuroradiology, Room L352, University of California at San Francisco Medical Center, 505 Parnassus Avenue, San Francisco, California 94143-0628, USA
3 shared publications- Adel M. Malek
Department of Radiology, University of California, San Francisco, USA
2 shared publications - Alastair J. Martin
Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
2 shared publications - Daryl R. Gress
Department of Neurology, University of California, San Francisco, 94143-0114, USA
2 shared publications
Latest Publications
- 1 June 2012
- Published by Springer Nature
- p. 27-41
Historical Account of Interventional Neuroradiology
- 1 February 2010
- Published by Wolters Kluwer Health in Stroke
- Vol. 41 (2) , e102-9
Evaluation of the Medtronic Exponent Self-Expanding Carotid Stent System With the Medtronic Guardwire Temporary Occlusion and Aspiration System in the Treatment of Carotid Stenosis
Background and Purpose— Embolic protection devices and improved stent technology have advanced the endovascular treatment of carotid artery disease. A combined analysis was performed of the MAVErIC ( M edtronic AVE Self-expanding Ca R otid Stent System with distal protection) I and II trials to evaluate the safety and feasibility of this system among patients at high risk for surgical endarterectomy. Methods— Four hundred ninety-eight patients were enrolled in the MAVErIC I (99 patients) and MAVErIC II (399 patients) studies from June 2001 to October 2004. The results were pooled for statistical analysis of a common primary end point, the 365-day rate of major adverse events. Clinical follow-up took place at 30 days, 6 months, and 365 days postprocedure. Results— The 365-day major adverse event rate, defined as death, stroke, or myocardial infarction within 30 days, and death, ipsilateral stroke, or myocardial infarction from days 31 to 365 was 12.5%. The incidence of neurological death through 365 days was 1.1%. The 30-day major adverse event rate was 5.4%. Subgroup analyses showed no notable differences in the 365-day major adverse event rate for symptomatic patients compared with asymptomatic patients. Conclusion— Treatment of carotid artery disease with carotid artery stenting with a self-expanding stent and distal embolic protection results in a low 30-day adverse event rate, including the occurrence of stroke in patients at high risk for carotid endarterectomy.
- 1 February 2010
- Published by Wolters Kluwer Health in Stroke
- Vol. 41 (2) , e102-9
Evaluation of the Medtronic Exponent Self-Expanding Carotid Stent System With the Medtronic Guardwire Temporary Occlusion and Aspiration System in the Treatment of Carotid Stenosis
Background and Purpose— Embolic protection devices and improved stent technology have advanced the endovascular treatment of carotid artery disease. A combined analysis was performed of the MAVErIC ( M edtronic AVE Self-expanding Ca R otid Stent System with distal protection) I and II trials to evaluate the safety and feasibility of this system among patients at high risk for surgical endarterectomy. Methods— Four hundred ninety-eight patients were enrolled in the MAVErIC I (99 patients) and MAVErIC II (399 patients) studies from June 2001 to October 2004. The results were pooled for statistical analysis of a common primary end point, the 365-day rate of major adverse events. Clinical follow-up took place at 30 days, 6 months, and 365 days postprocedure. Results— The 365-day major adverse event rate, defined as death, stroke, or myocardial infarction within 30 days, and death, ipsilateral stroke, or myocardial infarction from days 31 to 365 was 12.5%. The incidence of neurological death through 365 days was 1.1%. The 30-day major adverse event rate was 5.4%. Subgroup analyses showed no notable differences in the 365-day major adverse event rate for symptomatic patients compared with asymptomatic patients. Conclusion— Treatment of carotid artery disease with carotid artery stenting with a self-expanding stent and distal embolic protection results in a low 30-day adverse event rate, including the occurrence of stroke in patients at high risk for carotid endarterectomy.
- 29 August 2008
- Published by ASME International in Journal of Biomechanical Engineering
- Vol. 130 (5) , 051011
Numerical Simulations of Flow in Cerebral Aneurysms: Comparison of CFD Results and In Vivo MRI Measurements
Computational fluid dynamics (CFD) methods can be used to compute the velocity field in patient-specific vascular geometries for pulsatile physiological flow. Those simulations require geometric and hemodynamic boundary values. The purpose of this study is to demonstrate that CFD models constructed from patient-specific magnetic resonance (MR) angiography and velocimetry data predict flow fields that are in good agreement with in vivo measurements and therefore can provide valuable information for clinicians. The effect of the inlet flow rate conditions on calculated velocity fields was investigated. We assessed the internal consistency of our approach by comparing CFD predictions of the in-plane velocity field to the corresponding in vivo MR velocimetry measurements. Patient-specific surface models of four basilar artery aneurysms were constructed from contrast-enhanced MR angiography data. CFD simulations were carried out in those models using patient-specific flow conditions extracted from MR velocity measurements of flow in the inlet vessels. The simulation results computed for slices through the vasculature of interest were compared with in-plane velocity measurements acquired with phase-contrast MR imaging in vivo. The sensitivity of the flow fields to inlet flow ratio variations was assessed by simulating five different inlet flow scenarios for each of the basilar aneurysm models. In the majority of cases, altering the inlet flow ratio caused major changes in the flow fields predicted in the aneurysm. A good agreement was found between the flow fields measured in vivo using the in-plane MR velocimetry technique and those predicted with CFD simulations. The study serves to demonstrate the consistency and reliability of both MR imaging and numerical modeling methods. The results demonstrate the clinical relevance of computational models and suggest that realistic patient-specific flow conditions are required for numerical simulations of the flow in aneurysmal blood vessels.
- 29 August 2008
- Published by ASME International in Journal of Biomechanical Engineering
- Vol. 130 (5) , 051011
Numerical Simulations of Flow in Cerebral Aneurysms: Comparison of CFD Results and In Vivo MRI Measurements
Computational fluid dynamics (CFD) methods can be used to compute the velocity field in patient-specific vascular geometries for pulsatile physiological flow. Those simulations require geometric and hemodynamic boundary values. The purpose of this study is to demonstrate that CFD models constructed from patient-specific magnetic resonance (MR) angiography and velocimetry data predict flow fields that are in good agreement with in vivo measurements and therefore can provide valuable information for clinicians. The effect of the inlet flow rate conditions on calculated velocity fields was investigated. We assessed the internal consistency of our approach by comparing CFD predictions of the in-plane velocity field to the corresponding in vivo MR velocimetry measurements. Patient-specific surface models of four basilar artery aneurysms were constructed from contrast-enhanced MR angiography data. CFD simulations were carried out in those models using patient-specific flow conditions extracted from MR velocity measurements of flow in the inlet vessels. The simulation results computed for slices through the vasculature of interest were compared with in-plane velocity measurements acquired with phase-contrast MR imaging in vivo. The sensitivity of the flow fields to inlet flow ratio variations was assessed by simulating five different inlet flow scenarios for each of the basilar aneurysm models. In the majority of cases, altering the inlet flow ratio caused major changes in the flow fields predicted in the aneurysm. A good agreement was found between the flow fields measured in vivo using the in-plane MR velocimetry technique and those predicted with CFD simulations. The study serves to demonstrate the consistency and reliability of both MR imaging and numerical modeling methods. The results demonstrate the clinical relevance of computational models and suggest that realistic patient-specific flow conditions are required for numerical simulations of the flow in aneurysmal blood vessels.
- 1 January 2007
- Vol. 28 (1) , 146-151
Treatment of Unruptured Intracranial Aneurysms: A Nationwide Assessment of Effectiveness
BACKGROUND AND PURPOSE: With advances in neuroimaging, unruptured cerebral aneurysms are being diagnosed more frequently. Until 1995, surgical clipping of the aneurysm was the only treatment available. Since then, a less invasive endovascular technique has been found effective in a trial of ruptured aneurysms. No efficacy studies comparing the 2 procedures for unruptured aneurysms exist to guide clinical decisions. The objective of this study was to assess effectiveness and outcomes of endovascular versus neurosurgical treatment for unruptured intracranial aneurysms.
- 1 January 2007
- Vol. 28 (1) , 146-151
Treatment of Unruptured Intracranial Aneurysms: A Nationwide Assessment of Effectiveness
BACKGROUND AND PURPOSE: With advances in neuroimaging, unruptured cerebral aneurysms are being diagnosed more frequently. Until 1995, surgical clipping of the aneurysm was the only treatment available. Since then, a less invasive endovascular technique has been found effective in a trial of ruptured aneurysms. No efficacy studies comparing the 2 procedures for unruptured aneurysms exist to guide clinical decisions. The objective of this study was to assess effectiveness and outcomes of endovascular versus neurosurgical treatment for unruptured intracranial aneurysms.
- 1 June 2006
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 12 (2) , 123-130
Initial Clinical Experience with a New Complex-Shaped Detachable Platinum Coil System for the Treatment of Intracranial Cerebral Aneurysms
Endovascular coil occlusion of cerebral aneurysms is increasing as a viable treatment for both ruptured and unruptured aneurysms. The purpose of this study was to evaluate the safety and performance of a newer generation of complex-shaped, geometrically conformable, platinum coils, the TRUFILL DCS Detachable Coil System. From September 2000 to December 2002, 112 patients with 116 aneurysms, either ruptured or unruptured, deemed by an attending neuro-in-terventionalist to be acceptable candidates for endovascular coil embolization, were recruited into an open-label, prospective, multi-center, international registry study from 23 centers in Europe. Information on relevant clinical characteristics, device and procedure performance, and angiographic occlusion data were collected for all patients. An Independent Medical Monitor collected and reviewed information on all device- and procedure-related complications resulting in serious adverse events. Angiographic evaluation immediately following treatment of 116 aneurysms showed a mean ± SD percent of aneurysm occlusion of 93.5% ± 14.2, with 90.2% of aneurysms occluded at least 90%. The desired occlusion was achieved in 94.9% of aneurysms. Success was defined as the ability to obtain ≥ 90% aneurysm occlusion. The proportion achieving greater than 90% occlusion was statistically equivalent (at least as good) to the 80% registry standard. Complication rates were 6.9% device-related and 2.6% procedure-related. Only two complications were categorized as serious adverse events. The TRUFILL DCS coil system provided good to excellent complete occlusion of the aneurysm at initial treatment, as compared to other published studies, and proved effective and safe to use in treating both ruptured and unruptured cerebral aneurysms.
- 1 June 2006
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 12 (2) , 123-130
Initial Clinical Experience with a New Complex-Shaped Detachable Platinum Coil System for the Treatment of Intracranial Cerebral Aneurysms
Endovascular coil occlusion of cerebral aneurysms is increasing as a viable treatment for both ruptured and unruptured aneurysms. The purpose of this study was to evaluate the safety and performance of a newer generation of complex-shaped, geometrically conformable, platinum coils, the TRUFILL DCS Detachable Coil System. From September 2000 to December 2002, 112 patients with 116 aneurysms, either ruptured or unruptured, deemed by an attending neuro-in-terventionalist to be acceptable candidates for endovascular coil embolization, were recruited into an open-label, prospective, multi-center, international registry study from 23 centers in Europe. Information on relevant clinical characteristics, device and procedure performance, and angiographic occlusion data were collected for all patients. An Independent Medical Monitor collected and reviewed information on all device- and procedure-related complications resulting in serious adverse events. Angiographic evaluation immediately following treatment of 116 aneurysms showed a mean ± SD percent of aneurysm occlusion of 93.5% ± 14.2, with 90.2% of aneurysms occluded at least 90%. The desired occlusion was achieved in 94.9% of aneurysms. Success was defined as the ability to obtain ≥ 90% aneurysm occlusion. The proportion achieving greater than 90% occlusion was statistically equivalent (at least as good) to the 80% registry standard. Complication rates were 6.9% device-related and 2.6% procedure-related. Only two complications were categorized as serious adverse events. The TRUFILL DCS coil system provided good to excellent complete occlusion of the aneurysm at initial treatment, as compared to other published studies, and proved effective and safe to use in treating both ruptured and unruptured cerebral aneurysms.
- 19 April 2006
- Published by Springer Nature in Neuroradiology
- Vol. 48 (6) , 367-372
Intracranial angioplasty and stenting for cerebral atherosclerosis: new treatments for stroke are needed!
Intracranial atherosclerosis is a common cause of stroke. Recent technological developments offer improved methods for endovascular revascularization of symptomatic and asymptomatic cerebral artery stenosis. Identification of appropriate patients remains a diagnostic challenge, and our knowledge about the natural history of the disease remains limited. At this time, patients with significant intracranial stenosis should receive counseling on the benefits and risks of revascularization therapy. Ultimately, determination of which patients should undergo revascularization procedures will require carefully planned, randomized clinical trials.
- 19 April 2006
- Published by Springer Nature in Neuroradiology
- Vol. 48 (6) , 367-372
Intracranial angioplasty and stenting for cerebral atherosclerosis: new treatments for stroke are needed!
Intracranial atherosclerosis is a common cause of stroke. Recent technological developments offer improved methods for endovascular revascularization of symptomatic and asymptomatic cerebral artery stenosis. Identification of appropriate patients remains a diagnostic challenge, and our knowledge about the natural history of the disease remains limited. At this time, patients with significant intracranial stenosis should receive counseling on the benefits and risks of revascularization therapy. Ultimately, determination of which patients should undergo revascularization procedures will require carefully planned, randomized clinical trials.
- 1 December 2005
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 20 (Suppl. 2) , 140-147
Recent Advances in the Interventional Treatment of Acute Ischemic Stroke
Background: Acute ischemic stroke is a major cause of morbidity and mortality in Europe, North America, and Asia. Recent advances over the past decade have been made in the interventional approach to patients with a stroke. These include intravenous (IV) trials, intra-arterial (IA) trials, combined IV/IA trials, and newer devices undergoing current clinical evaluation to mechanically remove clot within the cerebral circulation. Methods: A summary of the latest interventional approaches to stroke, from the interventional neuroradiology perspective, is presented. Results of the major thrombolytic trials over the past decade are summarized. Newer devices and approaches for ischemic stroke patients, including the recently completed Phase 1/2 MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Trial are presented. Results: The Proact 1 and 2 trials involving IA thrombolytic therapy in patients who present with an acute middle cerebral artery stroke within 6 h from symptom onset have demonstrated significant benefit over the control group, for improved outcomes at 90 days. The MERCI trial has demonstrated, in 114 patients with moderate to severe strokes, that patients who are able to be recanalized have significant neurological improvement versus those who were not able to be recanalized. Conclusions: Continued advances in the interventional approach to acute stroke treatment, with further clinical trials, are warranted. Early reports are encouraging regarding both combination thrombolytic drug trials and mechanical device trials for these patients.
- 1 December 2005
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 20 (Suppl. 2) , 140-147
Recent Advances in the Interventional Treatment of Acute Ischemic Stroke
Background: Acute ischemic stroke is a major cause of morbidity and mortality in Europe, North America, and Asia. Recent advances over the past decade have been made in the interventional approach to patients with a stroke. These include intravenous (IV) trials, intra-arterial (IA) trials, combined IV/IA trials, and newer devices undergoing current clinical evaluation to mechanically remove clot within the cerebral circulation. Methods: A summary of the latest interventional approaches to stroke, from the interventional neuroradiology perspective, is presented. Results of the major thrombolytic trials over the past decade are summarized. Newer devices and approaches for ischemic stroke patients, including the recently completed Phase 1/2 MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Trial are presented. Results: The Proact 1 and 2 trials involving IA thrombolytic therapy in patients who present with an acute middle cerebral artery stroke within 6 h from symptom onset have demonstrated significant benefit over the control group, for improved outcomes at 90 days. The MERCI trial has demonstrated, in 114 patients with moderate to severe strokes, that patients who are able to be recanalized have significant neurological improvement versus those who were not able to be recanalized. Conclusions: Continued advances in the interventional approach to acute stroke treatment, with further clinical trials, are warranted. Early reports are encouraging regarding both combination thrombolytic drug trials and mechanical device trials for these patients.
- 1 March 2005
- Published by Wolters Kluwer Health in Stroke
- Vol. 36 (3) , 676-678
Magnetic Resonance Perfusion Tracks 133 Xe Cerebral Blood Flow Changes After Carotid Stenting
Background and Purpose— To compare magnetic resonance (MR) perfusion to gold-standard cerebral blood flow (CBF) determined by intra-arterial 133 Xe washout method. Methods— Eight patients with high-grade carotid stenoses underwent bolus-tracking MR perfusion and intra-arterial 133 Xe washout before and after carotid stenting. MR perfusion was compared with 133 Xe-CBF values using Pearson linear correlation analysis. Results— We observed a mean 37±38% increase in 133 Xe-CBF and a mean 19±27% increase in relative CBF (rCBF) by MR perfusion immediately after stent placement. Relative (percent) changes in MR-rCBF showed a close and linear correlation to those seen in 133 Xe-CBF ( r =0.91; R 2 =0.84; P =0.002). There was a trend for MR perfusion to underestimate change in CBF at higher relative changes in flow. Conclusion— Bolus-tracking MR perfusion correlates with 133 Xe-CBF in estimating postprocedural increases in blood flow but may underestimate the magnitude of the change with higher relative changes.
- 1 March 2005
- Published by Wolters Kluwer Health in Stroke
- Vol. 36 (3) , 676-678
Magnetic Resonance Perfusion Tracks 133 Xe Cerebral Blood Flow Changes After Carotid Stenting
Background and Purpose— To compare magnetic resonance (MR) perfusion to gold-standard cerebral blood flow (CBF) determined by intra-arterial 133 Xe washout method. Methods— Eight patients with high-grade carotid stenoses underwent bolus-tracking MR perfusion and intra-arterial 133 Xe washout before and after carotid stenting. MR perfusion was compared with 133 Xe-CBF values using Pearson linear correlation analysis. Results— We observed a mean 37±38% increase in 133 Xe-CBF and a mean 19±27% increase in relative CBF (rCBF) by MR perfusion immediately after stent placement. Relative (percent) changes in MR-rCBF showed a close and linear correlation to those seen in 133 Xe-CBF ( r =0.91; R 2 =0.84; P =0.002). There was a trend for MR perfusion to underestimate change in CBF at higher relative changes in flow. Conclusion— Bolus-tracking MR perfusion correlates with 133 Xe-CBF in estimating postprocedural increases in blood flow but may underestimate the magnitude of the change with higher relative changes.
- 1 January 2004
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 15 (1) , S77-S85
Intraarterial Thrombolysis Trials in Acute Ischemic Stroke
- 1 January 2004
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 15 (1) , S77-S85
Intraarterial Thrombolysis Trials in Acute Ischemic Stroke
- 1 January 2004
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 71 (Suppl_1) , S50
Intracranial stenting: which patients and when?
- 1 January 2004
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 71 (Suppl_1) , S50
Intracranial stenting: which patients and when?